 |
|
|
 |
|
New Cancer Drug Fights Tumors in Those With BRCA Mutations
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 "The drugs are given orally, and it still remains a question as to whether the drugs' benefits will extend beyond this narrow patient population," noted Dr. Eric Weiner, chief of women's cancers at the Dana-Farber Cancer Institute.
"These two studies are very exciting," Dr. Kelly Marcom, a breast oncologist with Duke Comprehensive Cancer Center and director of the Duke Hereditary Cancer Clinic in Durham, N.C., said. "It speaks to a really clever understanding of the biology of the cancer."
More information
Text Continues Below

For more information on BRCA1 and BRCA2 cancer, visit the U.S. National Cancer Institute. Page: << Prev | 1 | 2 | 3
|
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/24/2009
|
 |

SOURCES: J. Dirk Iglehart, M.D., department of surgery, Brigham and Women's Hospital, and the department of cancer biology, Dana-Farber Cancer Institute, Boston; Eric Weiner, M.D., chief, women's cancers, Dana-Farber Cancer Institute, Boston; Kelly Marcom, M.D., breast oncologist, Duke Comprehensive Cancer Center, and director, Duke Hereditary Cancer Clinic, Durham, N.C.; June 24, 2009, New England Journal of Medicine, online
|